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1. Introduction 
After the first cases of AIDS were described in 1981, the HIV pandemic rapidly expanded to 
become a major global public health problem with broad health, social, economic and 
developmental consequences that have not been seen with any other disease. In the 30 years 
that this disease has been known to mankind it has killed an estimated 25 million people 
and continues to affect not less than 33 million people many of whom could die if life saving 
therapies are not made available to them 1. The African continent has borne the largest 
impact of this  disease. Of the 33.3 million people that UNAIDS estimated were living with 
HIV in 2009, nearly 67% were living in Africa1. 
Pulmonary disease is a major contributor to the morbidity and mortality suffered by persons 
infected with HIV. It was the appearance of previously rare Pneumocytis pneumonia often 
accompanied by Kaposis sarcoma in previously healthy young gay men, intravenous drugs 
addicts and their sexual contacts that alerted the world to the new syndrome of the 
Acquired Immune Deficiency Syndrome (AIDS) caused by HIV 2,3,4,5,6. Before combination 
anti retroviral treatment (cART) became available a high proportion of HIV infected 
individuals would experience respiratory symptoms, and serious life threatening lung 
disease. Lung disease was often the index diagnosis that would point to the presence of HIV 
infection7,8. In general the incidence of serious pulmonary disease has declined following the 
wide availability of cART. For example in the USA rates of opportunistic infections 
decreased from 89.0 per 1000 person years in 1994-1997 to 25 per 1000 person years in 1998-
2002, and 13 per 1000 person years in 2003-20079. However, the incidence of many infectious 
diseases remain relatively high even in the cART era 10,11 and worryingly as HIV infected 
persons live longer, they appear to face an increased risk of non infectious lung diseases 
such as lung cancer, chronic obstructive lung disease and pulmonary arterial 
hypertension12,13.  
The range of pulmonary diseases that occur in HIV infected individuals is wide and 
includes infections, neoplasms, vascular lesions, interstitial pneumonias and obstructive 
airways disease. This chapter will summarize the current knowledge base on HIV associated 
lung disease including the burden and spectrum of the common diseases, diagnostic 
evaluation and approaches to treatment and prevention.  
2. Burden of pulmonary disease in HIV 
Prospective cohort studies carried out in the pre cART era out in North America and 
Western Europe documented a high incidence of both Pneumocytis and bacterial  
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Pneumonia Bacterial Streptococcus pneumoniae
Haempholius influenza 
Staphylococus aureus 
Pseudomonas aeruginosa 
Mycobacterium tuberculosis 
Others 
 Fungal Pneumocystic jirovecii
Aspergilus spp 
Cryptococcus neoformans 
Candida spp  
Mycoses Endemic to specific geographic areas 
(Histoplasma spp, Coccidiodes spp, Paracoccidiodes, 
Pencillium marneffei) 
 Viral Cytomegalovirus
Herpes Simplex 
Influenza 
Others 
 Parastic Toxoplasma gondii
Strongyloides stercoralis 
Malignacies Kaposis sarcoma
Lymphoma 
Lung cancer 
Other non infectious 
diseases 
Non specific Interstitial pneumonitis
Lymphoid Intersititial Pneumonitis 
Pulmonary arterial hypertension 
Chronic Obstructive Airway disease 
Others  
Table 1. Common pulmonary complications of HIV/AIDS. 
pneumonia14,15. The advent of cART markedly reduced the burden of both Pneumocytis and 
bacterial pneumonia but more so for Pneumocytis pneumonia16,17,18,.  
In contra distinction with situation in the developed world where Pneumocytis pneumonia 
was the hallmark of HIV lung disease, tuberculsosis (TB) has been the predominant disease 
in HIV infected persons in Sub – Saharan Africa. Tuberculosis case notification rates rapidly 
escalated as the HIV epidemic spread19, 20, 21,. In 2009 the World Health Organization 
estimated that HIV associated TB occurred in about 1.2 million people and was responsible 
for the deaths of about 200,000 people with nearly 85% of this burden occurring in Sub – 
Saharan Africa22.  
3. Clinical evaluation of HIV infected persons with respiratory symptoms 
3.1 History 
Even though advances have been made in medical technologies for the diagnosis of lung 
disease, a good clinical history remains essential in the clinical evaluation of HIV infected 
persons with lung disease. A thorough understanding of the patient’s illness may assist to 
narrow down the specific diagnosis behind the patient symptoms. It is important to establish if 
the patient presenting with respiratory symptoms already knows his or her HIV status and  
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Source WHO, Global Tuberculosis Report, 2010 
Fig. 1. TB Case Notification in Sub –Saharan Africa – 1990-2009. 
if so how long that status has been known. It is also important to know if that person has 
suffered opportunistic infections in the past, and if the patient is taking cART and preventive 
therapy for opportunistic infections. If the patient has been taking cART current and previous 
regimens must be elucidated and enquiries on adherence to current and previous cART made. 
The appearance of a lung opportunistic infection in a patient who has been on cART may point 
to a failing regimen. Since certain infections occur only in specific geographic areas a travel 
history should be obtained. Other risk factors for disease occurrence or for poor outcomes 
must as far as feasible be sought. These risk factors include intravenous drug use, alcohol 
abuse and tobacco smoking. The pre morbid health status must also be known.  
3.2 Clinical examination  
The clinical examination is intended to establish if serious lung disease is present and thus if 
urgent interventions are required. A common sense approach will help identify most 
patients with serious lung disease. Assessment of the patients’ mental status together with 
measurement of the respiratory rate, pulse, temperature, blood pressure and transcutaneous 
arterial oxygen saturation should rapidly reveal the presence or absence of serious life 
threatening lung disease. 
3.3 Laboratory tests 
The choice of laboratory and other tests to be carried out will depend on the clinical condition 
of the patient, the setting in which the patient is seen and the laboratory infrastructure 
available. Ideally most patients should have a plain chest radiograph to confirm the presence 
of lung disease and the extent of pulmonary involvement which will influence the placement 
of patients into specific risk groups for various outcomes and guide further management. 
Further medical tests may be carried out to identify co-morbid states or other organ 
involvement to assist with prognostication while others may be carried to diagnose the specific 
disease and thus assist in provision of targeted treatment. Tests designed to identify specific 
diseases include examination of body fluids such as sputum, blood, urine, bronchoalvelaor 
lavage fluid, pleural fluid and others  for pathogens using various stains, cultures, antigen and 
nucleic acid detection tests. Fiberoptic bronchoscopy (FOB), where available, with lavage, 
brushing and biopsy has found a special place in the evaluation of HIV infected persons with 
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respiratory symptoms. However FOB should not be used routinely in all HIV infected persons. 
This procedure may not provide treatment changing results in some settings.  
Evaluation of the patient with HIV Lung Disease 
 
Test /procedure Purpose Comment 
Chest x-ray Detection of lung disease/ 
severity assessment 
 Universally done 
CT scan Detection of lung disease 
/severity assessment 
Offers better detection and 
radiographic chacterization of 
lung disease/May be abnormal 
in the presence of a normal chest 
x-ray 
Pulse oximetry Severity assessment/ 
monitoring  
Shoulde be used in all patients 
with severe disease  
Arterial blood gases  Severity 
assessment/montoring 
Shoulde be used in all patients 
with severe disease 
Blood count (WBC, HB, 
Platelets)/ coagulation tests
Severity 
assessment/monitoring 
Shoulde be used in all patients 
with severe disease 
Renal and liver function 
tests 
Severity 
assessment/monitoring 
Shoulde be used in all patients 
with severe disease 
Induced Sputum gram stain 
and culture 
Microbiological aetiology  Shoulde be used in all patients 
with severe disease 
Blood culture Microbiological aetiology Shoulde be used in all patients 
with severe disease 
Antigen detection 
(Bllod/urine/sputum) 
Microbiological aetiolgy Especially for S. Pneumoniae and 
L. pneumophila sero group 1 
Serological tests Microbiological aetiology Most for the detection of 
“atypical pathogens”. Provide 
retrospective diagnosis  
Fiberoptic bronchoscopy 
witrh lavage, brushing and 
or biopsy 
Microbiological 
aetiology/diagnosis of non 
infectious disease 
Probably best reserved for 
patients with non diagnostic 
results with non invasive tests  
Open Lung Biopsy Histological 
diagnosis/Microbiological 
diagnosis 
Used mostly if bronchoscopy 
with TBB fails to provide a 
diagnosis 
Radio isotope studies Diagnosis of infectious /non 
infectious disease 
Gallium 67 citrate and 99m 
TCDTPA: expensive, time 
consuming and require complex 
infrastructure
Other tests (lung function 
tests) 
Diagnosis of non infectious 
disease (COPD) 
TLCO, KCO, FEV1, FVC: 
Sensitive but not specific for any 
lung disease
Table 2. Common tests and procedures for evaluating HIV associated lung disease. 
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4. Specific lung diseases 
4.1 Fungal pneumonia in HIV infected persons 
4.1.1 Pneumocytis pneumonia (PcP)  
The causative organism of Pneumocystis pneumonia, Pneumocystis jirovecii, has had an 
interesting history in terms of its taxonomy. Initially the pathogen was thought to be 
protozoan in nature. Later it was placed on the fungal group based on its nucleic acid profile 
and the name of the human pathogen was changed from Pneumocystis carinii to 
Pneumocystis jirovecii based on the understanding that the species that affects humans is 
distinctly different from that which affects other animals including cats23.  
4.1.1.1 Epidemiology 
Pneumocystis pneumonia was the dominant opportunistic infection in the pre cART era in 
the North America and Europe1, 2, 3,4,5,14,15. In contrast to the dominance of PcP in North 
America and Western Europe, other regions of the world and especially Sub Saharan Africa, 
the current epicentre of the HIV/AIDS epidemic, did not experience this surge of PcP with 
rates of PcP ranging from 0- 21% in the earlier case series and cohort studies 24,25,26,27,. In fact 
for a while this infection was thought to be absent from Africa28. As the HIV epidemic 
matured in Sub- Saharan Africa the prevalence of PcP in HIV infected patients appeared to 
have increased29,30,31, but the rates of this infection did not reach the levels that were 
observed in Western Europe and North America during the early years of the HIV 
epidemic. Currently PcP remains relatively rare in Sub – Saharan Africa, with prevalence as 
low as 1% being reported32, 33, 34,. The reasons for the low prevalence of PcP in Sub – 
Saharan Africa are not fully known but racial factors influencing susceptibility to the 
development of disease following infection or colonization may partly play a role. It is also 
worth noting that African populations have been documented to have a high prevalence of 
exposure to this pathogen and therefore the low rates of PcP in Sub –Saharan Africa is not 
the result of the absence of the pathogen from the African environment35. 
4.1.1.2 Risk factors 
Several studies have examined the risk factors for PcP in HIV infected individuals. These 
studies indicate that the risk of PcP is highest in those with declining CD 4 T cell count 
especially when the count falls below 200, unexplained fever, history of AIDs defining illness, 
presence of oral thrush and not being on prophylaxis or when prophylaxis fails36,37. HIV 
infected persons of the negroid race may have a lower risk of of PcP compared to Caucasians38. 
4.1.1.3 Clinical manifestations  
Symptoms 
Pneumocystis pneumonia usually presents with a sub acute onset of cough and shortness of 
breath. The cough is usually non productive or may be productive of scanty mucoid sputum 
while shortness of breath is slowly progressive and gradually limits activity. Many patients 
do not experience chest pain and do not have other constitutional disturbances, the 
symptom complex being largely dominated by shortness of breath.  
Signs 
The majority of patients will appear anxious when they are first examined. The breathing 
frequency is usually rapid and shallow. The pulse is also rapid but most often at the first 
evaluation the blood pressure is normal. Patients with PcP may have no fever at 
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presentation. Lung signs including crackles may be absent and even when present are non 
specific. There may be evidence of other opportunistic infections such ano genital herpetic 
ulcers and oral thrush.  
 
 
Fig. 2. Ano genital Herpetic Ulcers in a patient with PcP. 
4.1.1.4 Pneumocystis pneumonia – Diagnostic tests  
Radiologic imaging  
Patients suspected to have PcP should have a chest radiograph which typically shows 
bilateral interstitial or alveolar shadows in the mid zones with basal and apical sparing. In 
some situations PcP may be present without any obvious changes on the chest radiograph. 
In these situations high resolution chest CT scan may reveal typical abnormalities that may 
render the performance of a fiberoptic bronchoscopy procedure unwarranted39. Radiostopic 
studies using Gallium 67 scintigraphy, where available may help to distinguish lung 
infections from neoplastic and other diseases processes40. 
 
 
Fig. 3. Chest Radiograph showing shadows typical of PcP. 
Lung function testing  
Patients with PcP typically are hypoxemic and will desaturate further when exercised, an 
observation that has been used as a diagnostic test to predict the presence of this infection 41, 
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42. The measurement of diffusion capacity has also been found to be a useful diagnostic 
test43. 
Microbiological tests 
The definitive diagnosis of PcP is based on the identification of the pathogen in lung 
samples most commonly obtained through induced sputum, fiberoptic bronchoscopy or 
open lung biopsy. While some controversy still exists, fiberoptic bronchoscopy with lavage 
is the standard procedure for the detection of Pneumocystis jirovecii44. Both bronchial 
brushings and transbronchial biopsy during the bronchoscopy procedure may offer no 
added value in the evaluation of patients suspected to have PcP45. In general lower 
respiratory tract  specimens are subjected to either cytochemical staining using May-
Grünwald-Giemsa (MGG), toluidine blue-O (TOL), Papani-colou (PAP) and Grocott 
methenamine silver (GRO); immunofluorescent staining with monoclonal antibodies or 
PCR. However PCR may not distinguish infection from colonization46 .Examination of 
expectorated sputum remains a useful procedure for the microbiological diagnosis of PcP 
especially in low resource settings. When toluidine blue O staining of expectorated sputum 
is carried out the sensitivity approaches 70% and 35% compared with immunofluorescent 
staining and PCR respectively while specificity is 100% and thus in these settings 
examination of expectorated sputum may be a practical procedure for the diagnosis of PcP 
47. The yield from sputum examination may be increased if sputum production is induced 
following inhalation of hypertonic saline. In a meta analysis of diagnostic procedures for 
PcP, it was found that, compared with bronchoalvelaor lavage as the gold standard, 
examination of induced sputum had an overall sensitivity of 55.5% and a specificity of 98.6% 
with even better sensitivity at 67% versus 43.1% when comparing immunofluorescent 
staining with cytochemical staining. In settings where the prevalence of PcP is in the range 
of 25-60%, the positive and negative predictive values ranged from 86-96.7% and 66.2-89.8%, 
respectively, with immunofluorescent staining , and 79-94.4% and 53-83.5% with 
cytochemical staining48.  
Other tests 
The diagnosis of PcP may also be aided by the measurement of serum 1-3 beta D –Glucan, a 
cell wall component of most pathogenic fungi including Pneumocystis jirovecii which has 
been found to have a sensitivity of nearly 100% and specificity of about 96.4%. Therefore this 
test may be used as non invasive test for diagnosis of PcP49,50. This test may however not 
correlate with disease severity and should not be used to monitor patients on treatment87.  
Treatment of Pneumocystis Pneumonia 
The drug of first choice for the treatment of PcP remains cotrimoxazole. The recommended 
dose is 20mg per Kg body weight per day for the trimethoprim and 100 mg per Kg per day 
for the sulphamethoxazole, given in three or four divided doses. It has been reported, 
however that lower doses may be used without loss of efficacy and with the added 
advantage of a reduction in the rate of adverse events51. Second line treatment options for 
patients unable to tolerate high dose cotrimoxazole include clindamycin /primaquine and 
pentamidine but pentamidine may be associated with a greater risk of death52. Trimetrexate 
with folinic acid is generally well tolerated and has a clinical efficacy of about 70%53. Other 
second line therapies include atovaquone, dapsone, a combination product of trimethoprim 
and dapsone and eflornithine hydrochloride. A metanalysis of second line therapies, in 
patients who fail whatever initial treatment is given concluded that the combination of 
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clindamycin plus primaquine appears to be the most effective alternative treatment for 
patients with PcP who are unresponsive to conventional antipneumocystis agents54.  
Outcomes 
Pneumocystis pneumonia is a serious life threatening illness in persons living with HIV. The 
overall in hospital mortality of this illness is in the region of 10-13%. Among the factors that 
have been associated with death in patients with PcP include older age, recent injection drug 
use, total bilirubin of greater than 0.6 mg/dl, serum albumin of less than 3 g/dl, alveolar-
arterial oxygen gradient of equal or greater than 50 mm Hg, failure of cotrimoxazole 
treatment and the presence of co- morbidities such as bacterial pneumonia, Kaposis sarcoma 
and TB55,56,57. Patients who need to be admitted to the intensive care unit may suffer very 
high rates of deaths that could reach 80% within the ICU and up to 34 % three months post 
ICU admission58. The high mortality of patients who need to be mechanically ventilated 
appears to be associated with high APACHE II scores, high levels of Positive End Expiratory 
Pressures (PEEP),the presence of co- infection with CMV and lower CD 4 T cell counts 59,60. 
In an attempt to lower the mortality of PcP adjunctive systemic steroids are recommended61 
based on the results of clinical trials that documented a reduction in mortality in patients 
with moderate to severe disease62,63,64. Use of adjunctive steroids for the treatment of 
moderate to severe PcP has not been associated with increased long term mortality after the 
PcP episode nor with an increase in the incidence of other opportunistic infections65,66.  
There have been concerns that patients infected with Pneumocystis jirovecii that has 
developed mutations in the dihdropteroate synthase reductase gene may not respond as 
well to cotrimoxazole as patients whose pathogen does not carry these mutations. The 
majority of studies however indicate that the development of mutations on the 
dihdropteroate synthase reductace gene does not have an impact on the efficacy of 
cotrimoxazole in the treatment of PcP67,68 However it has been reported that DHPS 
mutations increase the risk of death in patients with PcP 69.  
It has been suggested that measurement of C- Reactive Protein (CRP) may be a useful 
prognostic marker in patients with PcP. In one study the levels of CRP were negatively 
correlated with arterial oxygenation (PaO2)70. 
Prevention  
Pneumocystis pneumonia in HIV infected persons is a preventable disease. The most 
effective treatment for the prevention of PcP is cART which reconstitutes the immune 
system and dramatically reduces the incidence of opportunistic infections including PcP16, 17, 
18, 19. Many HIV infected persons with risk factors for PcP will however require to be 
protected from this disease even if they have been placed on cART until CD4 T cell recovery 
has taken place. Although aeroslolized pentamidine and cotrimoxazole may have equal 
efficacy71, the preferred drug is cotrimoxazole72 but if this cannot be tolerated aerosolized 
pentamidine or atovaquone which have been  found to have similar efficacy may be used73. 
Mutation in the dihdrofolate reductase gene may however, lead to prophylaxis failures74,75. 
An alternative drug is dapsone which appears to have an efficacy equal to that of 
atovaquone but which may be less safe76. In patients receiving cART it has been 
recommended that prophylaxis for PcP be discontinued when the CD 4 T cell count climbs 
to 200 and above77 but recent studies suggest that prophylaxis may be discontinued when 
viral suppression is achieved and before the CD 4 T cell count reaches 200 and above78,79. 
These are reassuring observations because cotrimoxazole treatment may sometimes be 
associated serious life threatening complications including septic shock like syndrome80. 
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Complications 
Pneumocystis pneumonia may result in pneumothorax and pneumomediastinum both of 
which may be life threatening. These complications are thought to arise from newly formed 
cysts and bronchiectasis81  
4.1.2 Other fungal pneumonias in HIV infected persons 
Pneumonia caused by fungal pathogens, other than Pneumocystis jirovecii, though less 
common when compared with PcP and bacterial pneumonia is a frequent cause of 
morbidity and mortality in HIV infected persons. Fungal pathogens have been identified 
mostly in severely immunocompromised patients with CD 4 T cell count below 200 and the 
lung is often involved in a disease process that is often disseminated and or where multiple 
pathogens are causing disease. The mortality of fungal pneumonia in HIV infected persons 
is thus high.  
Of the fungal pathogens that have been associated with lung disease in persons living with 
HIV Cryptococcus may not only be the commonest pathogen but also the best characterized. 
This fungus is ubiquitous and is more famous for causing meningitis in severely 
immunocompromised patients. Lung disease due to Cryptococcus neorformans has been 
reported in all parts of the world and tends to occur in patients who have CD 4 T cell counts 
below 200 82,83,84, The other ubiquitous fungus that has been associated with lung disease in 
HIV infected persons is Aspergillus spp. Invasive Aspergillosis occurs most commonly in 
patients who have a severely depressed immune system and often participates in disease in 
partnership with other pathogens, as a disseminated infection which confers a high 
mortality85,86,87. Other fungal pathogens are mostly confined to specific geographic areas 
where they have been reported to cause significant morbidity and mortality in HIV infected 
persons. These fungal pathogens include Histoplasma spp, Coccidioides spp, 
Paracoccidiodies spp, Pencillium marneffei, Sporotrichosis spp and Blastomycosis88,89,90,. 
4.1.2.1 Clinical manifestations 
Pneumonia due to fungal pathogens, other than PcP, may follow an acute or sub acute course. 
The disease may be indistinguishable from pneumonia due to bacterial pathogens and TB. 
There are no clinical features that distinguish fungal pneumonia from pneumonia due to other 
pathogens. As in other forms of pneumonia the clinical syndrome is characterized by the 
presence of a cough, shortness of breath and fever as the primary symptoms. In the presence of 
disseminated disease or meningitis, headache, malaise, vomiting, confusion and wasting may 
be present. Specific examination of the chest may reveal tachypnea, signs of consolidation or 
the presence of a pleural effusion while chest radiography may reveal segmental, lobar or 
multi lobar consolidation, pleural effusion and or widespread reticular, nodular, reticulo – 
nodular or mixed alveolar and interstitial shadowing.  
4.1.2.2 Diagnosis 
The diagnosis of fungal pneumonia is based on the identification of fungal pathogens in 
respiratory specimens mostly obtained at fiberoptic bronchoscopy with bronchoalveolar 
lavage, bronchial brushings or occasionally through biopsies. To confirm a fungal pathogen 
the lung specimens are cultured in Sabborauds media or subjected to PCR. For Cryptococcal 
disease measurement of serum Cryptococal antigen may be yield positive results, especially 
when the disease is disseminated. Cryptococcal antigen in serum may be negative in 
isolated pulmonary disease.  
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4.1.2.3 Treatment 
The treatment of fungal pneumonia is dependent on the specific pathogen. Many classes of 
antifungal agents are now available for the treatment of serious fungal infections such as 
pneumonia. These include polyene antifungals such as amphotericin B, imidazole, triazole 
and thiazole antifungals such ketoconazole, fluconazole and itraconazole and echinocandins 
such as caspofungin, micafungin and anidulafungin 
4.1.2.4 Prevention 
The most important intervention for the prevention of fungal pneumonia is immune 
reconstitution using cART. While fluconazole has been used to prevent Cryptococcal 
infections in HIV infected persons it has not found widespread use and the efficacy may be 
suboptimal 91.  
4.2 Community Acquired Bacterial Pneumonia (CABP) in HIV infected persons  
4.2.1 Epidemiology 
Persons living with HIV have a high incidence of community acquired bacterial 
pneumonia92. Often CABP is the index diagnosis for HIV 93,94. With the advent of cART, 
the incidence of CABP fell but not as much as that of PcP in high income countries 
probably as a result of the presence of other risk factors that drive the susceptibility to 
bacterial pneumonia such as intravenous drugs use, smoking and alcohol abuse among 
HIV infected individuals95,96, 97,. In one French study, CABP was the cause of admission to 
the intensive care unit in 74% of 147 HIV infected patients admitted to ICU and surpassed 
PcP as the predominant cause of acute respiratory failure in the era of cART98. In African 
HIV infected patients CABP and in particular pneumococcal disease remains a major 
cause of morbidity and mortality. Autopsy studies have also documented high rates of 
bacterial pneumonia in HIV patients dying of lung disease. For example in one Brazilian 
autopsy study involving 240 HIV infected patients dying of respiratory failure, the cause 
of death was attributed to CABP in 36 % 99. In a similar study from one USA centre, 47 
patients with a pre mortem diagnosis of TB, CABP was deemed to have been the cause of 
death in 13 (26%)100.  
The incidence of lower respiratory tract infection increases as the CD4 T cell count declines 
and in the absence of ART. Acute bronchitis, CABP and PcP will be experienced by more 
than 80% of patients with a CD 4 T cell count of less than 200 even when these patients are 
provided with chemoprophylaxis101. Injecting drug users have an increased incidence of BP 
compared with other categories of HIV acquisition as are patients who smoke tobacco, have 
liver cirrhosis and have suffered a previous episodes of BP102,103. Smoking cessation has been 
found to be beneficial in reducing the incidence of BP in HIV infected persons104,105,106. Other 
factors that increase the risk of BP and in particular pneumococcal pneumonia include age, 
not being on HAART107 and neutropenia108. On the other hand the major risk factor for 
nosocomial pneumonia is the duration of hospitalization109,110. The pathogens commonly 
encountered in nosocomial pneumonia include Pseudomonas aeruginosa, Staphylococcus 
aureus, and Streptococcus pneumoniae.  
4.2.2 Clinical manifestations  
Community acquired bacterial pneumonia is largely an acute illness in which symptoms 
evolve rapidly over a few days 111.The classical symptoms include cough with or without 
sputum expectoration, chest pain which is often pleuritic in nature, difficulties in breathing 
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and rapid breathing primarily driven by the chest pain and fever. Clinical examination 
usually reveals a sickly patient who is febrile, tachypneic but usually not as tachypneic as 
the patient with PcP and who has a tachycardia. Specific examination of the chest may 
reveal dullness to percussion, with bronchial breath sounds and pulmonary rales over the 
affected lobe or lobes of the lungs.  
4.2.3 Imaging  
A plain chest radiograph should be obtained in all patients suspected to have bacterial 
pneumonia. The plain chest x-ray typically shows alveolar shadows with segmental, lobar 
or bronchopneumonic distribution and these changes are similar to those seen in HIV sero 
negative patients112. Although diffuse interstitial shadowing is less common this 
radiographic picture should not be used to exclude BP . Other changes that may be visible 
on the chest radiograph include the presence of pleural effusions and cavitations. No 
radiographic appearance is pathognomonic of any specific pathogen. The chest x-ray in BP 
is largely uninfluenced by cART but patients with CD 4 T cell count less than 200 are likely 
to have a bronchopneumonic picture. It has also been documented that bacteremic patients 
were more likely to have a lobar lesion and a higher CD4 T cell count above 200113,114. A 
chest CT scan may be very helpful. It may reveal lesions where the plain chest x-ray does 
not and have high specificity for certain infections such PcP115. 
4.2.4 Laboratory tests 
In hospitalized patients with CABP  total white blood cell count, should be measured. A 
total white cell count of below 4x109 /L has been associated with bacteraemia and excess 
mortality in HIV negative patients with community acquired pneumonia116 and may carry 
the same risk in HIV infected persons 117. Similarly thrombocytopenia (count of less than 
100,000 x109/l) appears to signify severe disease that necessitates aggressive treatment 
including admission to the intensive care unit118. Measurement of the CRP has not been 
documented to be able to discriminate between PcP and BP119, however, using the cut off 
value of 3ng/ml for procalcitonin and 246 mg/l for CRP one group of investigators 
reported an increased capability to distinguish BP from TB with a sensitivity of 81.8% and 
a specificity of 82.5% for the procalcitonin and 78.8% and 82.3% respectively for the 
CRP120. 
In hospitalized patients the measurement of blood urea, creatinine, sugar, albumin, 
bilirubin, AST and ALT helps to place patients in specific risk groups for poor outcomes 
using the CURB – 65121 and or Pneumonia Severity Index criteria122  
The microbiological diagnosis of CABP is dependent on the detection of the pathogen itself 
in culture, components of the pathogen (antigen) in body fluids or the antibody response to 
the pathogen. Relevant samples where the pathogen or its antigen may be identified include 
sputum, bronchoalveolar lavage fluid, bronchial brushings, lung biopsies or aspirates, 
blood, urine and pleural fluid. The interpretation of microbiological culture results from 
sputum and other respiratory secretions is hampered by the contamination of these samples 
by oropharyngeal bacterial colonizers and precautions must be taken to ensure that not only 
are good quality specimens obtained but also appropriate and proven methods for 
interpreting results of bacterial cultures from these specimens are followed. A good quality 
sputum sample is for example one that has low number of squamous cells and high number 
of polymorphonuclear cells123.  
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4.2.5 Sputum microbiologic testing 
In hospitalized patients, as far as feasible, sputum samples should be collected for gram 
staining and bacterial culture. If a sputum gram stain reveals a predominance of a pathogen 
with specific staining and morphological features (e.g. gram positive diplococci) this is 
highly predictive of the pathogen that is responsible for that episode of pneumonia. The 
sensitivity of sputum gram stain may reach 58%124. Sputum bacterial culture may be 
diagnostic in up to 34% of pneumonia episodes and be correlated with the organism isolated 
from a sterile site125. Compared with BAL and TBB the sensitivity and specificity of induced 
sputum is about 60% and 40% respectively126. Using quantitative bacterial culture the cut off 
for significant bacterial growth is usually considered to be 105 colony forming units per ml 
of sputum. In settings where PcP incidence may be low the fiberoptic bronchoscopy 
procedure may add little value to the examination of sputum for other pathogens127.  
4.2.6 Urinary antigen testing 
Urinary antigen tests are available for two bacterial pathogens: Streptococcus pneumoniae and 
Legionella pneumophila sero group 1. The urinary pneumococcal antigen test is a rapid test 
with good test performance parameters including a sensitivity in the region of 81%, specificity 
98%, positive (PPV) and negative predictive values (NPV) 98%, and 82%, respectively137. The 
urine pneumococcal antigen test may be positive many weeks after the pneumonia has 
resolved128.  The urinary antigen test for Legionella pneumophila sero group 1 has a sensitivity 
of 70-90% and a specificity of nearly 100% for the detection of this pathogen129  
4.2.7 Serological tests 
These tests are used primarily for the detection of atypical pathogens such as Mycoplasma 
pneumoniae130, Chlamydophila Spp and Legionella Spp other than Pneumophila Sero group 
1. The major draw back is that interpretation often requires comparison of results of acute 
and convalescent sera and thus may not be useful for clinical decision making.  
4.2.8 Fiberoptic bronchoscopy  
Fiberoptic bronchoscopy is a commonly used procedure for the evaluation of respiratory 
symptoms in HIV infected persons. Although the diagnostic yield may reach 74% only 
about 25% of bronchoscopies yield useful results that lead to a change in diagnosis and 
therapy131,132,133,. In situations where there are low rates of PcP and Kaposis sarcoma the 
fiberoptic bronchoscopy procedure may not yield additional results from that obtained 
through examination of expectorated sputum and other easily obtained body fluids145, 134, 
and therefore in such settings this procedure should be used judiciously.  
4.2.9 Fine needle transthoracic biopsy/aspiration 
This may be an underutilized procedure for the evaluation of respiratory symptoms in 
patients infected with HIV. The suitable patient for this procedure has a peripheral lesion 
close to the pleural membrane. The common complication with this procedure is 
pneumothorax which rarely requires pleural drainage135.  
4.2.10 The range of pathogens  
The range of pathogens involved in CABP in HIV infected persons is wide but the most 
common pathogens include Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella 
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pneumoniae, Haemophilus influenzae, H. parainfluenzae and Pseudomonas aeruginosa. 
Streptococcus pneumoniae is the most common pathogen isolated in 40- 60% of 
bacteriologically confirmed cases 136,137,138. In TB endemic areas TB is a common cause of 
acute community acquired pneumonia and should always be screened for in all patients 
presenting with this condition.  
Persons living with HIV are at increased risk of pneumococcal bacteraemia associated with 
community acquired pneumonia 139,140,141. However the impact of the bacteraemia on 
survival appears to be uncertain with some studies suggesting there is no increase in the risk 
of mortality while others have found an association between pneumococcal bacteraemia and 
mortality from community acquired pneumonia 142,154,155. Compared with sero negative 
patients HIV infected patients may be predisposed to harbouring penicillin resistant 
pneumococci155,143.  
Other pathogens that have been identified in HIV infected patients with community 
acquired pneumonia include:  
 Rhodococcus equi, a gram-positive, coryneform bacterium that causes zoonotic 
infection mainly in horses and foals. Most cases have been reported in case reports and 
or case series144, 145,146, 
 Enterococcus that may be vancomyicn resistant and associated with lung abscess and 
empyema147 
 Norcadia asteroides a gram positive filamentous rod which may cause chronic lung 
infection and may sometimes disseminate with associated high mortality 148,149. This 
infection may be difficult to diagnose. 
 Legionella pneumophila, although it remains unclear if HIV infected persons are at 
increased risk of infection or severe disease150 151 
 Mycoplasma pneumoniae which has been found in up to 17% of patients with 
community acquired pneumonia in both HIV negative and positive persons152, 153.  
 Moraxella catarrhalis though this pathogen appears to be an uncommon cause of 
community acquired pneumonia. In one large study only 4 cases among 2123 patients 
hospitalized over a nine year period were found to have this pathogen154  
 Community acquired Pseudomonas aeruginosa which has been described as a cause of 
severe and often fulminant community acquired pneumonia in patients who are 
severely immune suppressed and who may not have the traditional risk factors for this 
infection such as central lines and neutropenia155,156, 157.  
 Salmonella which has been described mainly in patients with Salmonella bacteraemia158. 
Often the HIV infected person has multiple pathogens causing the respiratory illness159, 160, 
161, 162 such as fungi, bacterial and viral pathogens.  
4.2.11 Treatment of community acquired bacterial pneumonia in HIV infected persons 
A holistic approach should be adopted to the care of HIV infected patients with community 
acquired pneumonia. The benefit of targeted anti microbial therapy are likely to accrue if 
attention is paid to hydration, oxygenation and nutritional needs among other needs of the 
patient. Control of symptoms such as pain, fever, vomiting and diarrhoea which often are 
part of the pneumonia syndrome in HIV infected persons will ensure patient comfort as 
specific antimicrobial treatment takes effect.  
The initial antimicrobial treatment will usually be chosen on an empiric basis and this choice 
should be based on the range of common pathogens isolated in the specific setting, the anti 
www.intechopen.com
HIV Infection in the Era of Highly Active  
Antiretroviral Treatment and Some of Its Associated Complications 
 
80
microbial susceptibility patterns of common pathogens, the cost of treatment, co morbid 
states and to some extent the experience of the treating practitioner. No studies have 
specifically examined the efficacy of various antibiotics for the management of CABP in HIV 
infected persons. Thus current practice is based largely on guidelines derived from studies 
involving HIV sero negative individuals and clinical experience. In TB endemic settings the 
combination of a beta lactam and a macrolides is preferred over the use of  fluoroquinolones 
to avoid masking TB. The combination of a beta lactam and a macrolide has been associated 
with better outcomes in HIV sero negative patients, but not in all studies163, and is 
recommended by the Infectious Disease Society of America and the American Thoracic 
Society164. Pneumococcal penicillin resistance may be more common in HIV infected 
persons165 but outcomes of treatment appear not to be influenced by the presence of 
intermediate levels of penicillin resistance166, 167.  
In patients with Rhodococcus infection at least two antimicrobial agents should be given 
simultaneously to treat this infection for a period of up to several months. The combinations 
of erythromycin and rifampin or imipenem and teicoplanin have been found to be the most 
effective treatments in Rhodococcus infections168. 
The anti microbial treatment of Nocardia asteroides involves the use of combinations with 
proven synergy, such as imipenem and amikacin, as the recommended initial therapy. 
4.2.12 Outcomes of community acquired bacterial pneumonia  
Several risk factors may work together to increase the risk of death in HIV infected patients 
receiving treatment for CABP. These risk factors include not being on ART, presence of 
pneumococcal antigen in urine for patients with pneumococcal pneumonia169 and comorbid 
states such as liver cirrhosis (mostly from alcohol abuse)170. Compared with HIV sero negative 
patients and in situations where health care delivery may be described as optimal HIV 
infection appears not to increase the mortality risk in hospitalized patients with Community 
Acquired Pneumonia and neither does it lead to prolongation of hospital stay171,172.  
In patients with acute respiratory failure admitted to the ICU, the risk of death is related to 
extent of organ failure such as need for mechanical ventilation and use of vasopressor 
agents rather than HIV parameters such as CD4 T cell count, HIV plasma viral load or use of 
ART173. 
Bacteremiac pneumococcal disease may confer a higher mortality risk but this has not been 
a consistent finding 155-159. Certain pathogens confer a greater risk of death. Compared with 
Streptococcus pneumoniae for example patients with Legionella, were found to have a 
higher risk of death probably from a greater prevalence of co morbid conditions174. 
Advancing age and low CD4 T cell count are also risk factors for severe disease and death in 
HIV infected patients including patients on ART175,176.  
It has been proposed that HIV infected patients be placed in a low risk immunosuppressed 
group for death and that in this group the Pneumonia Severity Index (PSI) can be used to 
define patients at risk of death similar with the use of this tool to define groups of patients at 
risk of death in HIV negative patients177, 178, 179.  
4.2.13 Prevention  
Vaccination is available for Streptococcus pneumoniae. The 23 valent polysaccharide 
vaccine appears to be effective in HIV infected persons in North America for reducing all 
cause pneumonia but those with plasma viral load of greater than 100,000 may not 
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benefit180,181,182, but the results of clinical trials have not always been consistent183. On the 
other hand African patients have not been documented to benefit from the 23 valent 
pneumoccal vaccine, 184, 185. To avoid the sub optimal efficacy of the 23 valent pneumococcal 
vaccine in African HIV infected persons a conjugate vaccine has been developed. A clinical 
trial of the 7 valent conjugate vaccine among Malawian patients found a protective efficacy 
of about 74% for the prevention of recurrent pneumococcal pneumonia 186 
The other intervention available for preventing BP in HIV infected persons is cotrimoxazole 
preventive therapy which is most effective in those with CD 4 T cell count below 200,187,188.  
4.2.14 Other issues 
Recent data suggests that recurrent BP may be associated with an increased risk of lung 
cancer in HIV infected persons probably related to the persistent or recurrent inflammation 
in the lung189. Parapneumonic effusions may be more common in HIV infected patients with 
community acquired pneumonia and patients with parapneumonic effusions may have 
more severe disease with higher rates of bacteraemia190.  
4.3 Mycobcaterial pneumonia in HIV infected persons 
4.3.1 Mycobacterium tuberculosis 
4.3.1.1 Epidemiology 
Tuberculosis is the most common opportunistic infection and the most common cause of 
death in HIV infected persons. The dramatic increase in the burden of TB in Sub – Saharan 
Africa has been largely blamed on the HIV epidemic191. However, other than for differences 
in magnitude, TB is the most common opportunistic infection that is observed in the first 
three months of initiation of cART in both Sub–Saharan Africa and the industrialized world 
of North America and Europe192,193. The TB and HIV epidemics are so intricately intertwined 
in Sub–Saharan Africa that care and control of one must be linked with the prevention and 
care of the other194. HIV influences TB by increasing the risk of reactivation of latent TB 
infection, rapid progression of new TB infection to disease and recurrent disease from both 
re-infection and relapse195.  
4.3.1.2 Clinical manifestations 
Pulmonary tuberculosis is characterized by the sub acute onset of cough with or without the 
production of sputum associated with systemic symptoms of fever, night sweating and loss 
of weight. The sputum may be stained with blood. These symptoms are not specific for TB. 
The only symptoms that are significantly more common in TB than in other patients are 
night sweats and loss of weight196. There may also be pleuritic chest pain but shortness of 
breath is uncommon until the late stages of the disease. The symptoms of TB are largely 
similar between HIV negative and positive patients, however, depending on the stage of 
HIV disease, HIV infected persons may have stigmata of the HIV infection such as oro-
pharyngeal candidiasis, oral hairy leukoplakia, a non specific skin rash, cutaneous Kaposis 
sarcoma and peripheral lymph node enlargement.  
There may be no significant signs unearthed on specific examination of the chest and even 
when present these signs are non specific. The chest radiograph is a sensitive but non 
specific test for detection of TB in both HIV infected and un infected individuals197. It may 
show a variety of lesions which to a large extent depend on the severity of the HIV related 
immunosuppresesion. When immune function is still relatively well preserved the classical 
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upper lobe fibrocavitary shadows may be seen. With advancing immune dysfunction the 
radiologic shadows become atypical and include mid and lower zone shadows, intrathoracic 
lymph node enlargement, pleural effusions, miliary shadowing among others lesions198, 199.  
4.3.1.3 Diagnosis of pulmonary TB  
Most TB occurs in middle and low income countries where conventional light microscopic 
examination of sputum using the Ziehl Nielsen stain is the primary diagnostic test. The test 
is rapid, relatively simple, inexpensive and highly specific in these settings, however, this 
test has provided inconsistent sensitivity results ranging from as low as 20%200 to as high as 
80%201 in comparison to culture confirmed TB and is more commonly negative in HIV 
infected individuals compared to HIV negative individuals202. Currently WHO recommends 
that two sputum specimens are obtained immediately the patient makes contact with the 
health care system. The examination of a third sputum specimen has not been found to add 
much value with the incremental yield of the third specimen not exceeding 4% 203. Similarly 
a morning specimen only marginally increases the diagnostic yield of smear microscopy 204 
and therefore may not be necessary in the evaluation of patients suspected to have TB. To 
increase the sensitivity of smear microscopy sputum may treated with bleach or sodium 
hydroxide and concentrated by centrifugation, or overnight sedimentation preceded by 
treatment with ammonium sulphate or bleach205. However the value of these sputum 
processes in HIV infected persons is not clear. The yield of sputum microscopy is 
consistently increased by up to 10% using fluorescence microscopy with auramine O or 
auramine – rhodamine stains 206 and recently fluorescence microscopy has been simplified 
by the development of Light Emitting Diode (LED) Fluorescence microscopy207. The Gold 
standard for TB diagnosis remains culture on solid or liquid media. Conventional culture on 
solid or liquid media for the diagnosis of TB is however a slow process that may take too 
long to reliably influence clinical decisions. The development of rapid liquid culture systems 
such as the Mycobaterial Growth Inhibitor Tube (MGIT) has improved the  turn around 
time and thus the clinical utility of culture for the diagnosis of TB208. The WHO recently 
recommended rapid liquid TB culture systems for the diagnosis of TB especially in HIV 
infected persons209. Although recommended by WHO as a bridge to fully automated liquid 
culture systems for TB diagnosis, non commercial culture systems such Mycobacteria 
Observation Drug Susceptibility (MODS), Nitrate Reductase Assays (NRAs), Thin layer 
Agar (TLA) and Colorimetric Redox Indicators (CRIs) systems do not decrease the time to 
TB diagnosis and drugs susceptibility results210. Even though the PCR technique has been 
used for a long time for the detection of TB, it is the automated cartridge based nucleic acid 
detection test called the Xpert MTB/Rif test that has the potential to revolutionize the 
diagnosis of TB especially in HIV infected persons. This test not only provides the diagnosis 
of TB in under two hours but also is able to indicate if there is likelihood of multi drug 
resistant TB based on the detection of mutations that confer rifampicin resistance. Diagnostic 
studies on this test suggest that it has an overall sensitivity of about 92.2% and a specificity 
of 99% using a single Xpert test. The sensitivity increases to 97.6% using three Xpert tests. 
Among HIV positive individuals the overall sensitivity of a single Xpert test has been 
reported to be about 94% compared to 98% in HIV negative individuals. For the detection of 
rifampicin resistance the sensitivity of this test is about 98%211,212. This test is now 
recommended as the initial test for the detection of pulmonary TB in HIV infected 
persons213. Although several serological tests are commercially available for the detection of 
TB, none has been found to have a consistently high sensitivity and specificity to replace 
smear microscopy and their use has recently been discouraged by WHO 214.  
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4.3.1.4 Treatment of TB in HIV infected persons 
Current treatment of pulmonary TB involves the use of combinations of 5 primary drugs: 
Isoniazid(H), rifampicin(R), ethambutol(E), pyrazinamide(Z),and streptomycin (S). The 
WHO and the International Standards of TB Care (ISTC) recommends a rifampicin based 
regimen made of RHZE given daily for two months followed by RH given daily, or two to 
three times weekly for six months for previously untreated patients215. With this regimen 
most HIV infected patients get cured with a lower risk of failure, relapse and acquired drug 
resistance216. Patients who have been treated previously must be assessed for risk of drug 
resistance, investigated for drug resistance using the Xpert MTB/Rif test, rapid molecular 
based line probe assays and culture, and treated with either primary, first line drugs if no 
drug resistance exists or with second line drugs if drug resistance, especially multi drug 
resistant TB, is present238.  
4.3.1.5 Drug resistant TB and HIV  
The WHO estimated that there were 400,000 cases of multi drug resistant TB, defined as 
TB bacilli that are resistant to both R and H, in 2009214. Although HIV per se appears not 
to be a risk factor for MDRTB, a link between MDRTB and HIV has been suggested by 
epidemiologic data from parts of Eastern Europe217. Outbreaks of MDRTB in HIV infected 
persons have been linked to nosocomial transmission of TB and have in general been 
characterized by high mortality among affected patients218. The more recent reports were 
from Southern Africa where a large majority of the patients were HIV infected, had 
extensive drug resistance (MDRTB with additional resistance to a fluoroquinolone and an 
injectable such as kanamycin, amikacin or capreomycin) and died within a few weeks 
after the diagnosis of XDRTB219, emphasizing the critical role of implementing robust 
measures to prevent TB transmission in situations where HIV infected persons receive 
care. 
4.3.1.6 Outcomes 
HIV infected PTB patients are at increased risk of death during treatment for TB. Up to 30% 
of such patients may die during treatment if no life prolonging ART is provided. The risk of 
death is higher in patients with smear negative disease and those with a lower CD 4 T cell 
count220. Life prolonging ART is able to dramatically reduce the deaths rates in HIV infected 
TB patients and the earlier it is given the better 221. Cotrimoxazole preventive therapy is also 
able to reduce the mortality of HIV associated TB222.  
4.3.1.7 Prevention 
HIV associated TB is a preventable disease. Several randomized clinical trials have 
demonstrated that TB can be effectively prevented using isoniazid given for 6-12 months in 
HIV infected persons223. With the advent of combined ART it was observed that TB 
incidence fell in persons on ART in North America and Europe. The fall in TB incidence has 
been observed to be greater in persons with a higher baseline CD4 T cell count, a lower base 
line viral load and robust immunological and virological responses224. Similar observations 
have been made in South Africa225. The combination of ART and Isoniazid Preventive 
Therapy (IPT) has been observed to confer greater protection against TB226 and provides 
further impetus to provide IPT in all HIV infected persons irrespective of whether they are 
or are not on ART. Currently there is no evidence that appropriately applied IPT leads to the 
expansion of isoniazid resistance227.  
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4.3.2 Other Mycobacteria 
4.3.2.1 Mycobacterium Avium Complex and other Non Tuberculous Mycobacteria 
Mycobacterium avium complex (MAC) is isolated with increasing frequency from respiratory 
specimens in HIV infected persons, however, the significance of isolating MAC from 
respiratory specimens is unclear. Criteria have been developed for defining clinical disease in 
patients who have non Tuberculous Mycobacteria isolated from respiratory samples228. HIV 
infected persons with pulmonary MAC are more likely to have fever, diffuse pulmonary 
abnormalities, lymphadenopathy and concurrent disease including disseminated MAC, PcP 
and BP compared with HIV negative individuals 229. These infections generally occur late in 
the course of HIV disease and confer a poor long term prognosis 230.  
4.4 Viral pneumonia 
Viral pathogens have also been implicated in HIV associated lung disease. These viruses 
have included Cytomegalovirus (CMV), Herpes Simplex Virus (HSV) and Influenza 
including H1N1. For CMV the difficult has been distinguishing infection from colonization. 
The most important risk factor for viral pneumonia is a CD 4 T cell count below 200. These 
pneumonias may be difficult to diagnose and carry a high mortality.  
4.4.1 CMV 
This is the most common virus that has been implicated in HIV associated pneumonia. The 
clinical presentation is similar to pneumonia due to other pathogens and is largely non 
specific. The symptoms include fever, shortness of breath, and cough. Pneumonia due to 
CMV may be the initial presentation of HIV disease231 and in the pre ART era, survival post 
CMV pneumonia, when successfully treated was short232, 233. Often CMV pneumonia is not 
recognized or diagnosed prior to death234,235. Patients with a high plasma viral load may 
also be at risk of CMV pneumonia236.  
The diagnosis of CMV may be problematic. When isolated in respiratory specimens such as 
bronchoalveolar lavage this virus may be a colonizer and not necessarily the cause of the 
lung disease 237. To diagnose respiratory disease the current consensus is that CMV should 
be isolated in lung secretions (BAL or brushes), and demonstrated to be available in 
histological specimens through immunohistochemistry or in situ hybridization in the 
presence of pulmonary infiltrates on the chest radiograph. The treatment of CMV involves 
the use of ganciclovir or forscanet.  
As with fungal pneumonia the most important intervention for the prevention of CMV 
pneumonia is immune reconstitution using anti- retroviral treatment. No chemo preventive 
intervention has been identified. Acyclovir has been tried but was not found to be efficacious238  
4.4.2 Herpes simplex 
Herpes simplex virus type 1 and type 2 have both been associated with HIV pneumonia. The 
pneumonia may occur in association with cutaneous herpes and thus represent disseminated 
disease239,240. Varicella pneumonia has been described and may present as a recurrent 
pneumonia241. 
4.5 Parasitic lung disease in HIV 
Lung disease caused by parasites may less common. The most common parasites that have 
been associated with HIV lung disease are Toxoplasma gondii and Strongyloides stercoralis. 
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Epidemiological studies to obtain good estimates of the incidence of these parasites in HIV 
infected persons have not been carried out. 
4.6 Non infectious HIV associated lung disease  
Several non infectious lung diseases have been observed in HIV infected persons. These 
diseases include pulmonary arterial hypertension, bronchiolitis obliterans organizing 
pneumonia, sarcoidosis and chronic obstructive pulmonary disease. The incidence of these 
diseases may be increasing as HIV infected individuals survive longer with cART.  
4.6.1 Interstitial pneumonitis  
The HIV syndrome is associated with an increased incidence of non specific interstitial 
pneumonitis and lymphoid interstitial pneumonitis, both of which may result from the chronic 
inflammatory state induced by HIV242,243. Lymphocytic Interstitial pneumonia in HIV infected 
persons may be associated with respiratory symptoms of cough and dyspnoea and cause lung 
function abnormalities244. The radiological picture is diffuse interstitial shadowing and a lung 
biopsy procedure is required for the diagnosis. The disease has been thought to be related to 
the host immune response245 and directly linked to HIV246. There is usually a predominance of 
CD8 positive T lymphocytes226. This entity may also occur as part of the immune reconstitution 
inflammatory syndrome247. It responds to systemic steroids and also resolves with ART248,249. 
The incidence has declined with the widespread use of anti-retroviral treatment250 
4.6.2 Non specific pneumonitis  
A non specific pneumonitis associated with cough and dyspnoea and diffuse interstitial 
shadowing on the chest x-ray often occurs in HIV infected persons. This disease entity may 
mimic PcP 251 and even appear to respond to PcP treatment252. However a search for 
Pneumocystis jirovecii is usually negative 253.  
4.6.3 Immune reconstitution inflammatory syndrome  
The immune reconstitution inflammatory syndrome represents an exaggerated immune 
response to infectious and non infectious agents as immune recovery occurs. The syndrome 
is characterized by the appearance of worsening symptoms and signs of specific infections 
as immune recovery takes place. While most episodes are mild, severe life threatening 
disease may occur. The syndrome has been described to occur with many infections 
including Pneumocystis jirovecii, CMV, TB and Cryptococcus 254,255,256,257.  
4.6.4 Pulmonary Arterial Hypertension (PAH)  
Pulmonary arterial hypertension associated with HIV is a rare clinical entity but when it 
occurs it leads to significant morbidity and mortality. The available literature is mostly 
based on case reports. This clinical entity appears to occurs at relatively high CD4 T cell of 
about 300. The clinical, radiographic and echocardiographic findings are similar to 
idiopathic PAH in HIV sero negative persons. Highly active antiretroviral therapy, 
bosentan, and prostaglandin therapy have all been reported to be beneficial in improving 
hemodynamic and functional status in HIV-related PAH258. In a French study the median 
survival of patients with HIV associated PAH receiving ART and PAH specific therapy was 
88% and 72% at 1 and 3 years respectively. There was better survival in patients with CD4 T 
cell count of greater than 200 and a higher cardiac index. Anti-retroviral therapy did not 
appear to influence hemodynamic parameters 259. 
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4.6.5 Pulmonary maligancies in HIV infected persons 
Both Kaposis sarcoma (KS) and non Hodgkins Lymphoma (NHL), the two AIDS defining 
malignancies (ADMs) have been associated with lung disease. Of the two malignancies KS 
has been the more common one. In HIV associated KS, the tumour most often afflicts the 
lung as part of a disseminated disease process but may also occur as a primary lung disease. 
Non Hodgikins lymphoma occurring as primary lung disease has been described in several 
case reports and series51. Persons living with HIV appear to be at increased risk of primary 
lung cancer, a non ADM52.  
Endobronchial Kaposis Sarcoma is seen in about 15% of patients with advanced HIV 
disease. The clinical presentation is indistinguishable from that of other pulmonary 
complications of HIV. Thus patients may present with cough, haemoptysis and dyspnoea. 
Both alveolar and interstitial shadows may be seen on the chest radiograph. Chest CT scans 
usually reveal the shadows better. The diagnosis requires visual detection of typical cherry 
red lesions at fiberoptic bronchoscopy. The lesions are usually not biopsied because of the 
risk of bleeding. Pulmonary KS usually occurs in the setting of disseminated KS and the 
prognosis is typically poor.  
Non Hodgikins lymphoma involving the lung has been reported in case series and cohorts. 
The clinical presentation is usually non specific and includes fever, weight loss, dyspnea, 
generalized lymphadenopathy, chest pain and cough. The chest raidiograph reveals nodular 
lesions or interstitial shadows. The diagnosis of lymphoma is more reliably made on open 
lung biopsy. In the pre – ART era the diagnosis of NHL carried with it a poor prognosis 
even with specific lymphoma treatment 260.  
The risk of lung cancer in HIV infected persons appears to be increased and this increase 
may not be fully explained by smoking261. Although the data is scanty, recurrent 
pneumonia, through the promotion of chronic infection has been found to be associated 
with the increased risk of lung cancer in HIV infected persons262. The incidence of lung 
cancer, may have increased in post HAART era263. However the incidence of lung cancer in 
HIV infected women appears not to be higher that that in HIV un infected women and the 
driver of the lung cancer risk is tobacco smoking and not the HIV infection264. HIV infected 
patients with primary lung cancer are younger, tend to present with aggressive and 
advanced disease and have poorer outcomes265,266. 
4.6.6 Chronic obstructive pulmonary disease 
Respiratory symptoms and functional abnormalities are common in patients infected with 
HIV including those on combined anti –retroviral therapy. A recent observational study 
documented respiratory symptoms and functional abnormalities in 47.3% and 64.1% of 
study participants respectively. Irreversible airways obstruction compatible with COPD, 
independently associated with pack years smoked, intravenous drug use and the use of anti 
–retroviral therapy was found in 21% of study participants267. In patients with obstructive 
airways disease, HIV infection appears to confer a higher risk of moderate but not severe 
dyspnoea268. 
4.6.7 Bronchiolitis obliterans organizing pneumonia 
Bronchiolitis obliterans organizing pneumonia (BOOP) is a disease of the small airways 
characterized by intraluminal polyps of myxoid connective tissue. The concomitant 
occurrence of BOOP with HIV has been described in a few case reports. In the cases 
reported, the clinical manifestations have included sub acute onset of dyspnoea which 
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progressed to respiratory failure, non productive cough and fever. The most common chest 
radiographic findings included bilateral mixed interstitial and alveolar shadows. When 
these patients are investigated for infection, no pathogens are found and empiric antibiotic 
therapy is not effective. The diagnosis of BOOP is made at open lung biopsy. Patients 
respond very well to corticosteroids at a dose of about 1 mg/Kg for up to three months269. 
4.6.8 Hypersentivity pneumonitis 
Case reports of hypersensivity pneumonitis associated with drugs used in the management 
of HIV infection including dapsone270, efavirenz271 and other anti retrovirals272 have been 
published. The burden of illness and or death caused hypersensivity pneumonitis in HIV 
infected persons is currently unclear.  
4.6.9 Sarcoidosis 
Sarcoidosis is a multi system disease in which tissues are infiltrated with non caseating 
granulomas. The lung is a common target of sarcoid lesions. Pulmonary sarcoidosis 
associated with HIV has been reported in case reports and series273,274. Many of the 
sarcoidosis case reports have appeared in the post HAART era and it is unclear if this entity, 
in the ART context is related to immune recovery. In patients who use adulterated drugs 
talc granulamotosis must be considered in the differential diagnosis of interstitial lung 
disease. This clinical entity is indistinguishable from opportunistic infections and requires 
examination of lung biopsy specimens which show granulomas with intracellular talc 
crystals275. 
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